In addition to this, the FDA released a warning in June 2011 that Victoza had been linked to thyroid cancer. Based on the FDA warning, the agency’s Adverse Event Reporting System had documented 25 claims of Victoza-attributed thyroid cancer from February 2010 to September 2011. More inputs here: victoza-lawsuits.com

1. PATIENTS TAKING VICTOZA AT HEIGHTENED RISK
FOR PANCREATIC AND THYROID PROBLEMS

2.  In March 2013, the U.S. Food and Drug Administration
(FDA) announced the results of a research study that
enumerated the dangerous side effects of Victoza which
include pancreatitis. Acute pancreatitis may lead to grave
organ damage and even death. Because of this, the FDA
advised patients who are using Victoza, as well as those
who have their dosage increased, should carefully
observe signs and symptoms of pancreatitis. The
symptoms include persistent severe abdominal pain that
may radiate to the back, and which may or may not be
accompanied by vomiting.

3.  In addition to this, the FDA released a warning in June 2011 that Victoza
had been linked to thyroid cancer. Based on the FDA warning, the agency’s
Adverse Event Reporting System had documented 25 claims of Victoza-
attributed thyroid cancer from February 2010 to September 2011.
 Before this, the FDA put in a supplementary warning in May 2011 to the
“Warning and Precautions” section of the Victoza label because of the
drug’s association with renal damage. The warning states that renal
impairment “has been reported post-marketing, usually in association
with nausea, vomiting, diarrhea, or dehydration which may sometimes
require hemodialysis.” The additional label warns the medical community
to “use caution when initiating or escalating doses of Victoza in patients
with renal impairment.”

4.  Victoza is a medication for type 2 diabetes treatment.
Victoza is a medication used to treat type 2 diabetes. The
dynamic ingredient in Victoza, liraglutide, works in the
same way as a glucagon-like peptide-1 (GLP-1). The role of
this substance is for glucose metabolization and insulin
secretion in the pancreas. The FDA approved Victoza in
January 2010. From the time of its approval, Victoza turned
out to be one of the most widely-used diabetes drugs on the
market, boosting up its sales to $670 million in 2011.

5.  Victoza’s manufacturer, Novo Nordisk, is presently a target for filing of Victoza lawsuit
due to the drug’s adverse side effects. Novo Nordisk, the manufacturer of Victoza, is
currently a subject for filing of Victoza lawsuit due to the drug’s negative side effects.
Organ failure, permanent disability, and death are some of the gravest side effects that
have been linked to Victoza. The most widely-encountered Victoza side effects are
pancreatitis, pancreatic cancer, thyroid cancer and kidney failure. The webpage
victoza-lawsuits.com discusses more information about these issues.
 References:
 nhs.uk/conditions/diabetes-
type2/pages/medicinesideeffects.aspx?condition=diabetes&medicine=victoza&preparati
on=
 victoza.com/learn/usage-guidelines.aspx
 chealth.canoe.ca/drug_info_details.asp?brand_name_id=5519